| Q89860704 | A CRISPR Test for Rapidly and Sensitively Detecting Circulating EGFR Mutations |
| Q57074582 | ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients |
| Q90019492 | ALK detection in lung cancer: identification of atypical and cryptic ALK rearrangements using an optimal algorithm |
| Q99583003 | Accuracy of lung cancer staging in the multidisciplinary team setting |
| Q61810150 | Advances in theranostic biomarkers for lung cancer from clinical to molecular pathology |
| Q58802261 | Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy |
| Q96228738 | Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma |
| Q97525750 | Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance |
| Q57826835 | Biomarkers in the diagnosis of pleural diseases: a 2018 update |
| Q99582653 | Biomarkers predictive value in early stage non-small cell lung cancer |
| Q89622178 | Broad-based genomic sequencing in advanced non-small cell lung cancer in the dock |
| Q93008125 | CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays |
| Q59135403 | Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer |
| Q92747731 | Comparison of cytocentrifugation supernatant fluid and formalin-fixed paraffin-embedded tissue for targeted next-generation sequencing |
| Q98386285 | Current management of RET rearranged non-small cell lung cancer |
| Q89737022 | Detection of circulating tumor cells in patients with lung cancer using metallic micro-cavity array filter: A pilot study |
| Q90484059 | Diagnostic Accuracy of Droplet Digital PCR and Amplification Refractory Mutation System PCR for Detecting EGFR Mutation in Cell-Free DNA of Lung Cancer: A Meta-Analysis |
| Q99582705 | EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes |
| Q94450834 | EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors |
| Q90735910 | Evaluation of Two EGFR Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer |
| Q92466727 | Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer |
| Q91724653 | Immunocytochemistry for predictive biomarker testing in lung cancer cytology |
| Q89622486 | Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity |
| Q64923816 | Implementation of cancer next-generation sequencing testing in a community hospital. |
| Q64063912 | Isolated 5' Signals Are an Atypical Pattern To Be Considered as Positive for ALK Rearrangement: A Brief Report of Three Cases and Review of the Literature |
| Q90405006 | Latest development of liquid biopsy |
| Q90639806 | Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells |
| Q64094304 | Lung Molecular Cytopathology: EGFR and Beyond |
| Q59125634 | Making cytology specimens solid materials for testing predictive marker of immunotherapy in NSCLC |
| Q61813525 | Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients |
| Q94512759 | Molecular testing for lung adenocarcinoma: Is it time to adopt a "plasma-first" approach? |
| Q61800801 | Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancer |
| Q95260235 | Novel ALK-specific mRNA in situ hybridization assay for non-small-cell lung carcinoma |
| Q91395219 | Plasma-thrombin cell blocks: Potential source of DNA contamination |
| Q88220643 | Precision oncology in non-small-cell lung cancer: opportunities and challenges |
| Q91538499 | Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations |
| Q93155445 | RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples |
| Q92635410 | Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review |
| Q92925160 | Small lung tumor biopsy samples are feasible for high quality targeted next generation sequencing |
| Q99607554 | Somatic mutation detection efficiency in EGFR: a comparison between high resolution melting analysis and Sanger sequencing |
| Q99365876 | Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice |
| Q91845628 | TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer |
| Q104289124 | Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer |
| Q93016463 | The Potential of Radiomics Nomogram in Non-invasively Prediction of Epidermal Growth Factor Receptor Mutation Status and Subtypes in Lung Adenocarcinoma |
| Q61810136 | The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients |
| Q90843191 | The diagnosis of non-small cell lung cancer in the molecular era |
| Q92536325 | The importance of molecular characterization in lung cancer |
| Q90843203 | The utilization of cytologic and small biopsy samples for ancillary molecular testing |
| Q90697039 | Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020 |
| Q59798130 | Tumor mutational burden in non-small cell lung cancer-the pathologist's point of view |
| Q97648949 | Use of cytology centrifuged supernatants improves cost and turnaround time for targeted next generation sequencing |
| Q99590522 | [Chinese Expert Consensus on Next Generation Sequencing Diagnosis for Non-small Cell Lung Cancer (2020 Edition)] |